Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Jean-Marc Nabholtz


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


J.A. Nabholtz1, K.A. Alsaleh1, A. Bounedjar2, M. Oukkal3, H.M. El-Zawahry4, K. Bouzid5, H. Abdel Razek6, H. Mahfouf7, A. Bensalem8, A. Saadeddin9, T. Filali10, B. Larbaoui11, O. Abulkhair12, M. Al-Foheidi13, H. Boussen14, J. ayari15, M. Ghosn16, N. Abdel-Aziz1, F. Dabouz17, S. Kullab1

Author affiliations

  • 1 Oncology Center, King Saud University Medical City (KSUMC), 94970 - Riyadh/SA
  • 2 Medical Oncology, CHU Blida, Blida/DZ
  • 3 Medical Oncology, CHU Beni-Messous, 16206 - Algiers/DZ
  • 4 Medical Oncology, National Cancer Institute-Cairo University, 11796 - Cairo/EG
  • 5 Oncology Center, Centre Pierre et Marie Curie, 16000 - Algiers/DZ
  • 6 Internal Medicine, King Hussein Cancer Center, 11941 - Amman/JO
  • 7 Medical Oncology, EPH Rouiba, Rouiba/DZ
  • 8 Oncology, CHU Dr Benbadis, 25000 - Constantine/DZ
  • 9 Oncology, King Abdulaziz Medical City-Riyadh, 11426 - Riyadh/SA
  • 10 Oncology, CHU Constantine, 25000 - Constantine/DZ
  • 11 Medical Oncology, CAC Emir Abdelkader, Oran/DZ
  • 12 Oncology, Specialized Hospital Medical Center, 11586 - Riyadh/SA
  • 13 Medical Oncology, King Khalid National Guard Hospital - King Abdul Aziz Medical City, 21423 - Jeddah/SA
  • 14 Oncology, Abderrahmen Mami Hospital, 2080 - Ariana/TN
  • 15 Department Of Medical Oncology, Université de Tunis El Manar, Faculté de Médecine de Tunis, 1007, Tunis, Tunisie The military hospital of Tunis,, 1081 - tunis/TN
  • 16 Hematology-oncology, Hotel Dieu de France Hospital, 1107 2020 - Beirut/LB
  • 17 Clinical Operation, International Cancer Research Group, sharja/AE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4733


NA chemotherapy (CT) +/- anti-Her2 treatment of operable breast cancer (BC) is considered a standard option in the management of BC. However, pathologic complete response (pCR) rates with CT in HR+/Her2- BC are usually low: 7% (Luminal A) to 16% (Luminal B). Alternatively, NA endocrine therapy (ET) has not been established as a standard treatment because of low pCRs.


This is a multicenter phase III, 3rd generation NA trial performed in 34 centers and 7 countries of Middle-East and North Africa (MENA Region). The objective is to investigate the potential role of adding Palbociclib to ET (Fulvestrant +/- Goserelin) compared to ET alone as NA therapy of HR+/Her2- operable BC sensitive to ET. The primary endpoint is pCR with the hypothesis that the addition of Palbociclib would increase the pCR rate from 5% to 15%. Clinical/radiological response, conservative surgery rate, safety, disease-free and OS are secondary endpoints. Exploratory endpoints encompass biomarker serial analysis of liquid biopsies with Quantum Optic and DNA methylation technologies.


A total of 400 pre and post-menopausal pts with stage II and IIIA are planned to be recruited. Oncotype DX is performed upfront in order to eliminate CT candidates. All pts with a recurrence score (RS) < 31 are treated with Fulvestrant (500 mg Day (d.) 1, 14, 28 then q. 28 d. (+/- Goserelin 3.6 mg q.28 d.) for 4 months. Pts with responding/stable disease are then randomized in double blind fashion to Fulvestrant (+/- Goserelin) with either Palbociclib 125mg po daily 3 weeks/4 or placebo. Four additional cycles are delivered before surgery The trial was initiated in 2018. As of April 2019, 196 patients have been enrolled. The majority of them (60%) are pre/peri menopausal. The mean age is 50.5 years (range: 25-83). RS of < 31 was reported in 75% of cases. So far, 96 pts have completed the induction ET and were randomized to ET with or without Palbociclib. End of accrual is expected by end of 2019.


SAFIA trial aims to evaluate whether or not the addition of a CDK 4/6 inhibitor to pts sensitive to ET would validate a neo-adjuvant strategy without CT in luminal operable BC.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

International Cancer Research Group (ICRG).


Pfizer, AstraZeneca and Genomic Health.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.